SpringWorks Therapeutics (NASDAQ:SWTX), which is reportedly in takeover talks with Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), has received FDA approval for the drug mirdametinib for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback